Kamila Jaremek

Ms. Kamila Jaremek

Nicolaus Copernicus University, Toruń, Kujawsko-Pomorskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAlicja Sękowska
Alicja Sękowska
KCKrzysztof Czyzewski
Krzysztof Czyzewski
KJKamila Jaremek
Kamila Jaremek
PZPatrycja Zalas-Więcek
Patrycja Zalas-Więcek
OZOlga Zajac-Spychala
Olga Zajac-Spychala
JSJan Styczyński
Jan Styczyński
Background: Klebsiella pneumoniae is a nosocomial pathogen that causes severe infections in immunocompromised patients. The aim of the study was to conduct a microbiological and clinical analysis of K. pneumoniae infections in children with malignancies or undergoing hematopoietic cell transplantation in Poland. Methods: We conducted a retrospective, multicenter study including children and adolescents under 19 years old treated between 2012 and 2021. We analyzed patients’ characteristics, microbiological data, and the outcomes of antibiotic therapy. Results: A total of 9121 newly diagnosed children were treated for malignancy and 1697 pediatric patients underwent hematopoietic cell transplantation. K. pneumoniae infections were diagnosed in 527 patients. Their overall incidence was 4.86% in pediatric hematology and oncology patients and 4.95% in patients who underwent hematopoietic cell transplantation. The incidence of infection was higher in patients with acute leukemia than with solid tumors (7.8% vs. 4.1%; OR = 2.0; 95% CI = 1.6–2.4; p < 0.0001). The most frequent source of infection was in the urinary tract at 55.2%. More than 57% of K. pneumoniae strains were extended-spectrum β-lactamase-positive and almost 34% were multidrug-resistant. Infections with K. pneumoniae contributed to death in 3.22% of patients. Conclusions: K. pneumoniae is one of the most critical pathogens in children suffering from malignancies or undergoing hematopoietic cell transplantation. The incidence of multidrug-resistant K. pneumoniae strains is increasing and contributing to poor clinical outcome.

24 September 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
Joanna ZawitkowskaJoanna Zawitkowska
Joanna Zawitkowska
KDKatarzyna Drabko
Katarzyna Drabko
KCKrzysztof Czyzewski
Krzysztof Czyzewski
MDMagdalena Dziedzic
Magdalena Dziedzic
KJKamila Jaremek
Kamila Jaremek
JSJan Styczyński
Jan Styczyński
Viral infections can be a serious complication of therapy in children with acute lymphoblastic leukemia (ALL). In this study, we focused on the incidence and the profile of viral infection in children with ALL treated in 17 pediatric oncology centers in Poland in the two-year periods of 2018–2019 and 2020–2021. We also compared the frequency of viral infections in 2018–2019 to that in 2020–2021. In 2020–2021, a total of 192 children with ALL had a viral infection during intensive chemotherapy. A total number of 312 episodes of viral infections were diagnosed. The most common infections detected in the samples were: COVID-19 (23%), rhinovirus (18%), and respiratory syncytial virus (14%). COVID-19 and BK virus infections were the reason for the death 1% of all patients. In 2018–2019, a total of 53 ALL patients who had a viral infection were reported and 72 viral events were observed, mainly adenovirus (48.6%), rotavirus (31.9%), and herpes zoster (8.3%). No deaths were reported during this period. The cumulative incidence of viral infections in 2018–2019 was 10.4%, while for 2020–2021, it was 36.7%. In conclusion, a high incidence of COVID-19 infection was observed among pediatric patients with ALL in Poland. The mortality rate in our material was low. The viral profile in ALL children undergoing chemotherapy can be useful for clinicians to improve prophylactic and therapeutic strategies.

Verified
Journal Article
Open access
PDF file
ETEwelina Truszkowska
Ewelina Truszkowska
KCKrzysztof Czyzewski
Krzysztof Czyzewski
KDKatarzyna Derwich
Katarzyna Derwich
KJKamila Jaremek
Kamila Jaremek
OGOliwia Grochowska
Oliwia Grochowska
OZOlga Zajac-Spychala
Olga Zajac-Spychala
Background: Acinetobacter, specifically A. baumannii, are becoming a great threat to hospitalized patients due to increasing antibiotic resistance. The aim of this study was to describe the epidemiology, clinical characteristics, antimicrobial susceptibility pattern and outcome of Acinetobacter infections in pediatric cancer patients and hematopoietic stem cell transplant (HSCT) recipients in Poland. Methods: A total of 125 episodes of Acinetobacter species infections were reported in patients <18 years treated in Polish pediatric hematology and oncology centers over a period from 2012 to 2023. Infections were subdivided into oncohematological disease (OHD) group (n = 106; 84.8%) and HSCT group (n = 19; 15.2%). Each episode represented a separate infection event; therefore, a patient who was infected more than once during the course of treatment was counted for each infection episode. Results: A. baumannii is the most common Acinetobacter species in all groups. The most common diagnoses in OHD group were acute lymphoblastic leukemia (ALL) (n = 32; 30.2%) and acute myeloid leukemia (AML) (n = 13; 12.3%). The most common underlying diseases that were indication for HSCT were hemophagocytic lymphohistiocytosis (n = 3; 15.8%) and neuroblastoma (n = 3; 15.8%). Mortality was significantly higher in the HSCT group compared to the OHD group. In the OHD group, deaths did not correlate with the type of antibiotic, with an exception for gentamicin, which correlated with higher mortality. In the HSCT group, deaths did not correlate with the type of antibiotic, except for levofloxacin that was correlated with a higher mortality rate. Conclusions: Acinetobacter infections are a great danger to immunocompromised patients. More research is needed in order to prevent and treat antibiotic-resistant bacteria.

16 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ETEwelina Truszkowska
Ewelina Truszkowska
KCKrzysztof Czyzewski
Krzysztof Czyzewski
KDKatarzyna Derwich
Katarzyna Derwich
KJKamila Jaremek
Kamila Jaremek
OGOliwia Grochowska
Oliwia Grochowska
OZOlga Zajac-Spychala
Olga Zajac-Spychala
Background: Acinetobacter, significantly A.baumannii, are becoming a great threat to hospitalized patients due to increasing antibiotic resistance. The aim of this study was to describe the epidemiology, clinical characteristic, antimicrobial susceptibility pattern and outcome of Acinetobacter infections in pediatric cancer patients and HSCT recipients in Poland. Methods: a total of 125 episodes of Acinetobacter species infections were reported in pa-tients < 18 years treated in Polish pediatric hematology and oncology centers over a pe-riod from 2012 to 2023. Infections were subdivided into oncohematological diseases (OHD) group (n=106; 84,8%) and hematopoietic stem cell transplant (HSCT) group (n=19; 15,2%). Results: A.baumannii is the most common Acinetobacter species in all groups. The most common diagnoses of infected patients in OHD group were: ALL (n=32; 30.2%) and AML (n=13; 12.3%). The most common underlying disease that was indication for HSCT among infected patients were hemophagocytic lymphohistiocytosis (n=3; 15.8%) and neuroblastoma (n=3; 15.8%). In OHD group, deaths did not correlate with the type of antibiotic, with an exception for gentamicin, which correlates with higher mortality. In HSCT group, deaths did not correlate with the type of antibiotic, except for levofloxa-cin that was correlated with higher mortality rate. Mortality was significantly higher in the HSCT group compared to the OHD group. Conclusions: Acinetobacter infections are a great danger to immunocompromised pa-tients. More research is needed in order to prevent and treat antibiotic resistant bacteria.

25 September 2025 in Acta Haematologica Polonica
Verified
Journal Article
Closed access
KJKamila Jaremek
Kamila Jaremek
AMAgata Marjańska
Agata Marjańska
OGOliwia Grochowska
Oliwia Grochowska
NBNatalia Bartoszewicz
Natalia Bartoszewicz
KCKrzysztof Czyżewski
Krzysztof Czyżewski
JSJan Styczyński
Jan Styczyński

Verified
Journal Article
Open access
PDF file
Anna Frączkiewicz-JabłońskaAnna Frączkiewicz-Jabłońska
Anna Frączkiewicz-Jabłońska
MRMonika Richert-Przygońska
Monika Richert-Przygońska
KJKamila Jaremek
Kamila Jaremek
KCKrzysztof Czyzewski
Krzysztof Czyzewski
WBWanda Badowska
Wanda Badowska
JSJan Styczyński
Jan Styczyński
Background: Staphylococcus spp. represent the most prevalent Gram-positive organisms in children with malignancies or undergoing haematopoietic cell transplantation (HCT), contributing to significant morbidity and mortality. This study aimed to assess the epidemiology, risk factors, treatment strategies, and outcomes of staphylococcal infections (SIs) in paediatric haemato-oncology (PHO) and HCT patients in Poland over a 12-year period. Methods: A retrospective, multicentre study was conducted across 17 paediatric oncology centres in Poland. The clinical and microbiological data of patients under the age of 18, diagnosed with malignancies or post-HCT, were analysed for confirmed SI between 2012 and 2023. The variables assessed included demographics, underlying conditions, infection type and source, antimicrobial susceptibility, treatment, and 30-day infection-free survival. Results: Among 1725 patients with SI, 1433 were PHO and 292 were HCT patients. The cumulative incidence of SI was 12.7% in PHO and 14.3% in HCT patients (p = 0.008). The 30-day survival rate was significantly higher in PHO compared to HCT patients (98.4% vs. 93.2%, p < 0.001). Most deaths were caused by S. epidermidis, S. haemolyticus, and S. hominis, predominantly involving methicillin-resistant coagulase-negative Staphylococci (MRCNS). Multivariate Cox regression identified undergoing HCT (HR = 3.0, 95% CI: 1.6–5.6, p < 0.001) and treatment of infection > 10 days (HR = 2.0, 95% CI: 1.1–3.6, p = 0.019) as independent risk factors for mortality. Conclusions: Staphylococcal infections pose a significant challenge in paediatric oncology and transplant populations. Optimising prevention, diagnostics, and antimicrobial therapy is crucial for improving outcomes in these high-risk groups.